Table 1 General characteristics of included participants.
Variable | Total (n = 75) | MAFLD (n = 38) | Controls (n = 37) | P-value |
|---|---|---|---|---|
Age (years), median (IQR) | 45 (30–57) | 54 (48–59) | 30 (27–40) | <0.001 |
Gender - males, no. (%) | 35 (46.7) | 18 (47.4) | 17 (46) | 0.902 |
BMI (kg/m2), median (IQR) | 26.2 (22.2–30.3) | 30.3 (28.1–33.3) | 22.1 (20.1–24.8) | <0.001 |
Metabolic syndrome, no. (%) | 31 (41.3) | 29 (76.3) | 2 (5.4) | <0.001 |
SBP (mmHg), median (IQR) | 124 (116–134) | 132 (122–147) | 120 (113–124) | <0.001 |
DBP (mmHg), median (IQR) | 78 (74–84) | 82 (78–89) | 75 (71–78) | <0.001 |
Hypertension, no. (%) | 35 (46.7) | 30 (79) | 5 (13.5) | <0.001 |
Diabetes, no. (%) | 16 (21.3) | 16 (42.1) | 0 (0) | <0.001 |
Impaired fasting glucose, no. (%) | 5 (6.7) | 3 (7.9) | 2 (5.4) | 1 |
Dyslipidemia, no. (%) | 38 (50.7) | 26 (68.4) | 12 (32.4) | 0.002 |
SteatoTest Score, median (IQR) | 0.39 (0.13–0.635) | 0.635 (0.512–0.713) | 0.13 (0.08–0.19) | <0.001 |
SteatoTest | – | – | – | <0.001 |
S0, no. (%) | 37 (49.3) | 0 (0) | 37 (100) | – |
S1, no. (%) | 10 (13.3) | 10 (100) | 0 (0) | – |
S2, no. (%) | 17 (22.7) | 17 (100) | 0 (0) | – |
S3, no. (%) | 11 (14.7) | 11 (100) | 0 (0) | – |
Hepatic Steatosis (Ultrasonography), no. (%) | 38 (50.7) | 38 (100) | 0 (0) | < 0.001 |
